Kevin Gray to Marijuana Abuse
This is a "connection" page, showing publications Kevin Gray has written about Marijuana Abuse.
Connection Strength
11.437
-
Cannabis Use Disorder in Adolescents. Child Adolesc Psychiatr Clin N Am. 2023 01; 32(1):13-20.
Score: 0.660
-
Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend. 2021 01 01; 218:108383.
Score: 0.575
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.538
-
Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend. 2018 11 01; 192:59-66.
Score: 0.494
-
The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine. Addict Behav. 2018 10; 85:26-30.
Score: 0.485
-
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
Score: 0.476
-
Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
Score: 0.467
-
Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017 10; 81:53-58.
Score: 0.459
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.455
-
Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States. Drug Alcohol Depend. 2017 07 01; 176:14-20.
Score: 0.452
-
Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. Am J Addict. 2017 Mar; 26(2):136-144.
Score: 0.444
-
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
Score: 0.429
-
Gender Differences in Internalizing Symptoms and Suicide Risk Among Men and Women Seeking Treatment for Cannabis Use Disorder from Late Adolescence to Middle Adulthood. J Subst Abuse Treat. 2016 07; 66:16-22.
Score: 0.415
-
Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder. J Subst Abuse Treat. 2016 Apr; 63:72-7.
Score: 0.411
-
Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav. 2015 Jun; 45:119-23.
Score: 0.386
-
Objective and subjective memory ratings in cannabis-dependent adolescents. Am J Addict. 2015 Jan; 24(1):47-52.
Score: 0.384
-
Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014 Nov; 39(2):211-23.
Score: 0.375
-
Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents. Am J Drug Alcohol Abuse. 2014 Jul; 40(4):285-91.
Score: 0.365
-
Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav. 2013 Mar; 38(3):1788-91.
Score: 0.331
-
A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug; 169(8):805-12.
Score: 0.325
-
Reactivity to in vivo marijuana cues among cannabis-dependent adolescents. Addict Behav. 2011 Jan-Feb; 36(1-2):140-3.
Score: 0.285
-
N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict. 2010 Mar-Apr; 19(2):187-9.
Score: 0.275
-
Challenges in quantifying marijuana use. Am J Addict. 2009 Mar-Apr; 18(2):178-9.
Score: 0.256
-
Cue reactivity in young marijuana smokers: a preliminary investigation. Psychol Addict Behav. 2008 Dec; 22(4):582-6.
Score: 0.252
-
Tolerability and effects of oral Delta9-tetrahydrocannabinol in older adolescents with marijuana use disorders. Pharmacol Biochem Behav. 2008 Nov; 91(1):67-70.
Score: 0.244
-
Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints. Psychol Addict Behav. 2022 Aug; 36(5):515-525.
Score: 0.157
-
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
Score: 0.153
-
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. Psychol Addict Behav. 2022 Aug; 36(5):505-514.
Score: 0.151
-
The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug Alcohol Depend. 2020 07 01; 212:107993.
Score: 0.139
-
Investigating a novel fMRI cannabis cue reactivity task in youth. Addict Behav. 2019 02; 89:20-28.
Score: 0.124
-
Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend. 2018 06 01; 187:270-277.
Score: 0.121
-
A multi-site proof-of-concept investigation of computerized approach-avoidance training in adolescent cannabis users. Drug Alcohol Depend. 2018 06 01; 187:195-204.
Score: 0.120
-
Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict. 2016 Jan; 25(1):69-75.
Score: 0.103
-
Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 01; 156:29-37.
Score: 0.100
-
Preliminary evidence that computerized approach avoidance training is not associated with changes in fMRI cannabis cue reactivity in non-treatment-seeking adolescent cannabis users. Drug Alcohol Depend. 2019 07 01; 200:145-152.
Score: 0.032